No title
The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention, from long-established immunisation programs to emerging
